226 results on '"De Lena M"'
Search Results
2. Thrombospondin-1 Is a Key Mediator of mTOR Inhibitor-Associated Induction of T and B Lymphocyte Regulatory Phenotype in Kidney Transplanted Patients.: Abstract# B1170
3. Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis
4. MICROVESICLES DERIVED FROM ENDOTHELIAL PROGENITOR CELLS PROTECT KIDNEYS AND PANCREATIC ISLETS FROM ISCHEMIA-REPERFUSION INJURY: O115 (F.12-5)
5. Randomised Clinical Trial of Adjuvant Chemotherapy in Patients with Node-Negative, Fast-Proliferating Breast Cancer
6. pS2—A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer
7. Simultaneous determination of 5′-deoxy-5-fluorouridine, 5-fluorouracil and its main metabolites in body fluids by HPLC
8. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
9. Clinical and histopathological characterization of an unique case of primary leiomyosarcoma of the lung
10. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II-III randomized trial
11. Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Group (SICOG) phase III trial.
12. Cisplatin-gemcitabine vs. cisplatin-gemcitabine-vinorelbine vs. cisplatin-gemcitabine in advanced non-small-cell lung cancer. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial.
13. MANTA1 STUDY: PACLITAXEL MAINTENANCE AFTER FIRST LINE CHEMOTHERAPY WITH ANTHRACYCLINES PLUS PACLITAXEL IN METASTATIC BREAST CANCER PATIENTS
14. EPIRUBICIN vs EPIRUBICIN + CISPLATIN vs EPIRUBICIN + LONIDAMINE vs EPIRUBICIN + CISPLATIN + LONIDAMINE AS FIRST LINE TREATMENT IN ADVANCED BREAST CANCER (BC) PATIENTS. A RANDOMIZED MULTICENTER PHASE III TRIAL WITH A FACTORIAL DESIGN.
15. GEMCITABINE + VINORELBINE(GV) VS. GEMCITABINE + PACLITAXEL(GT) VS. GEMCITABINE(G) VS. PACLITAXEL(T) IN ELDERLY NSCLC PATIENTS.
16. CISPLATIN, GEMCITABINE, VINORELBINE (PGV) vs CISPLATIN AND GEMCITABINE (PG) vs CISPLATIN, GEMCITABINE, PACLITAXEL (PGT) IN ADVANCED NSCLC: FINAL ANALYSIS A PHASE III TRIAL
17. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study
18. Hepatitis C virus infection in patients with B-cell lymphoproliferative disorders
19. Response And Survival In Advanced Breast Cancer After Two Non-Cross-Resistant Combinations
20. Prospective study with HEXA-CAF combination in ovarian carcinoma
21. T3b-T4 breast cancer: factors affecting results in combined modality treatments
22. Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer
23. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer.
24. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
25. Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
26. High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.
27. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.
28. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.
29. Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer.
30. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.
31. Cytosolic Levels of Estrogen-Regulated pS2 Protein in Breast Cancer: Correlation with Tumor Proliferative Activity.
32. Correlation between ERICA and DCC Assay in Hormone Receptor Assessment of Human Breast Cancer.
33. Adjuvant hormonetherapy for slow proliferating node-negative breast cancer patients. Results of the phase III trial of NCl-Bari
34. Adjuvant polychemotherapy vs control for node-negative, rapidly proliferating breast cancer: Combined analysis of two phase III trials
35. Taxol, gemcitabine and vinorelbine, a very active platinum free triplet in naive patients with Non Small Cell Lung Cancer
36. Taxol-gemcitabine-vinorelbine (TGV) given every 2 weeks in chemo-naive advanced NSCLC. A SICOG phase I study
37. Oxaliplatin (L-OHP) and irinotecan (CPT-11) with 6s-leucovorin (IFA)-modulated 5-fluorouracil (FU) i.v. bolus every 2 weeks: a dose-finding study in patients (pts) with gastrointestinal malignancies
38. Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial
39. Phase I/II study of gemcitabine plus mitoxantrone in advanced breast cancer (ABC)
40. Gemcitabine + vinorelbine (GV) vs vinorelbine (V) alone in elderly or frail non-small cell lung cancer (NSCLC) patients. Interim analysis of a SICOG phase III trial
41. Isolation, Characterization and Pro-Angiogenic Activity of Microvesicles (MVs) Derived from Human Pancreatic Islets.
42. Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts)
43. 823 A full navelbine oral (NVB oral) treatment in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC).
44. Simultaneous determination of 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5,6-dihydro-5-fluorouracil in serum by liquid chromatography with diode array UV detection
45. Heterogeneity of intratumour proliferative activity in primary breast cancer: Biological and clinical aspects
46. A shared effort toward better quality of care. The Consensus Conference on Breast Cancer Follow-up
47. Impact of Postoperative Radiation Therapy on Survival in Patients With Complete Resection and Stage I, II, or IIIA Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
48. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial [corrected] [published erratum appears in LANCET ONCOL 2006 Oct;7(10):797].
49. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma
50. Plenary 3: Impact of Radiation on Survival After Complete Resection of Non–Small-Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial, ANITA 1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.